136
0 Kommentare
Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial - Seite 3
1 Based on the treatment policy estimand (primary statistical approach): treatment effect regardless of treatment adherence or initiation of other anti-obesity therapies
2 Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies
Company announcement No 34 / 2020
Anzeige
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von globenewswire
1 im Artikel enthaltener WertIm Artikel enthaltene Werte